Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130468 · ClinicalTrials.gov registry record · Phase 4
TREAD-20: Trial of Hyalgan Three Injection-Regimen for the Treatment of Knee Pain Due to Osteoarthritis
A Phase 4 study of Osteoarthritis, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00130468 is a Phase 4 study of Osteoarthritis that has completed, run by Sanofi. The registered enrollment target is 150 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00130468, a Phase 4 study of Osteoarthritis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the efficacy and safety of intra-articular injections of 20 mg/2mL dose HYALGAN in patients with pain due to osteoarthritis (OA) of the knee.
Conditions Studied
Interventions
- DRUG Hyalgan (sodium hyaluronate)
Study Locations (1)
New Jersey
- Sanofi-Aventis Inc - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130468
The ClinicalTrials.gov registry entry for NCT00130468 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (82% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Hyalgan (sodium hyaluronate) is the first listed.
NCT00130468 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00130468 about?
NCT00130468 is a clinical study titled "TREAD-20: Trial of Hyalgan Three Injection-Regimen for the Treatment of Knee Pain Due to Osteoarthritis". This study will evaluate the efficacy and safety of intra-articular injections of 20 mg/2mL dose HYALGAN in patients with pain due to osteoarthritis (OA) of the knee.
What is the current status of trial NCT00130468?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2004-11. Estimated completion is 2006-05.
What conditions does trial NCT00130468 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT00130468?
The interventions under investigation include: Hyalgan (sodium hyaluronate) (DRUG).
Who is sponsoring clinical trial NCT00130468?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00130468 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketorolac in Upper Extremity Tendinopathy and Arthropathy
RECRUITING · Phase 4
-
Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department
RECRUITING · Phase 4
-
Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA)
ACTIVE NOT RECRUITING · Phase 4
-
Duloxetine in Osteoarthritis (OA) Pain
COMPLETED · Phase 4
-
Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement
COMPLETED · Phase 4
-
The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.